PAXIL Drug Patent Profile

When do Paxil patents expire, and when can generic versions of Paxil launch?

Paxil is a drug marketed by Apotex and is included in four NDAs.

The generic ingredient in PAXIL is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paxil

A generic version of PAXIL was approved as paroxetine hydrochloride by APOTEX on July 30^th, 2003.

Summary for PAXIL

US Patents:	0
Applicants:	1
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PAXIL

US Patents and Regulatory Information for PAXIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	PAXIL	paroxetine hydrochloride	CAPSULE;ORAL	020885-001	Oct 9, 1998		DISCN	Yes	No
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031-002	Dec 29, 1992	AB	RX	Yes	No
Apotex	PAXIL	paroxetine hydrochloride	CAPSULE;ORAL	020885-004	Oct 9, 1998		DISCN	Yes	No
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999	AB	RX	Yes	No
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031-003	Dec 29, 1992	AB	RX	Yes	No
Apotex	PAXIL	paroxetine hydrochloride	CAPSULE;ORAL	020885-002	Oct 9, 1998		DISCN	Yes	No

International Patents for PAXIL

See the table below for patents covering PAXIL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H11228571	NEW COMPOUND
Lithuania	96007
Netherlands	1013749
Spain	2209428
Australia	697982
Australia	6307299

PAXIL Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

Overview
PAXIL (paroxetine) is a selective serotonin reuptake inhibitor (SSRI), primarily prescribed for depression, anxiety, OCD, and related disorders. Initially developed by GlaxoSmithKline (GSK), it remains a significant product in the antidepressant market. Its patent expired in most major markets around 2013–2014, increasing generic competition and impacting revenue streams. Analyzing its current investment viability requires an assessment of market position, patent landscape, generics impact, and regulatory environment.

Market Position and Sales Trends
PAXIL's global sales peaked before patent expiration, generating over $1.4 billion in annual revenue worldwide during 2004–2006. Post-patent, sales declined sharply due to generic entry, with GSK reporting worldwide sales of approximately $100 million in 2021 for “Paxil” or “paroxetine” formulations. Generics now dominate, reducing GSK’s direct revenues but expanding access and prescribing rates due to reduced costs.

Patent and Regulatory Landscape
The PAXIL patent expiration facilitated generics, leading to a steep decline in branded sales by 2014. However, brand retention persists through formulation patents, secondary patents, or formulations targeting specific indications. Regulatory approvals for generics in the US and EU were granted circa 2014, leading to rapid market share erosion. GSK’s shifting strategy involves licensing, biosimilars, or branded extensions in newer markets.

Competition and Market Dynamics
The antidepressant market is mature, with major players including Pfizer’s Zoloft, Eli Lilly’s Prozac, and generic brands. PAXIL faces stiff competition from established generics, which typically cost 10–20% of branded prices. Newer drugs like vortioxetine or esketamine target treatment-resistant depression or specific symptom clusters but lack the broad revenue base PAXIL once commanded.

R&D and Lifecycle Outlook
No recent new chemical entity development for paroxetine is publicly announced. R&D investments for PAXIL-specific innovations are minimal. Future revenues depend on market share retention in existing indications, off-label use, or niche applications.

Financial Fundamentals and Investment Risks

• Revenue Stability: Post-patent decline limits revenue; GSK's net sales for PAXIL fell sharply post-2014. Investments in related branding or niche indications may sustain minimal revenues.
• Profit Margins: Highly dependent on generic pricing trends; margins are thin due to price erosion.
• Patent Strategy: Use of secondary patents is limited, with patent cliffs now fully realized.
• Regulatory Risks: Generic market entries are unaffected by regulatory hurdles; risks lie in regulatory changes affecting approvals or pricing policies.

Investment Scenario
Considering the current market environment, direct investment in PAXIL itself is unlikely to generate significant returns due to patent expiry and generic competition. However, investment in GSK’s pipeline or related biosimilars and niche formulations could indirectly benefit from PAXIL's market footprint. Value might also exist in licensing or acquisition scenarios targeting legacy products with residual market shares.

Key Considerations for Investors

• Focus on companies with existing blockbuster antidepressants or expanding portfolios.
• Seek opportunities where patents or formulations protect niche markets.
• Monitor regulatory trends influencing generic pricing and market access.
• Beware of declining revenues and narrow profit margins on legacy drugs.

---

Key Takeaways

• PAXIL’s patent expiration led to significant revenue decline and expanded generic penetration.
• No active development or new formulations signal long-term revenue erosion.
• Market competition primarily from generics constrains profitability.
• Investment value lies in related pipeline assets or licensing opportunities.
• Regulatory and policy shifts may influence future market access and pricing.

---

FAQs

1. Is PAXIL still commercially viable?
Direct sales have diminished significantly due to generic competition. Only niche markets or formulations with patent protections retain some value.

2. Are there ongoing lawsuits or patent disputes related to PAXIL?
Most patent disputes concluded by 2014. No major litigations currently target PAXIL as a branded product.

3. Can new indications or formulations revive PAXIL’s revenue?
Limited prospects exist due to patent expirations and market saturation; most new research involves novel drugs.

4. How does GSK’s strategy impact PAXIL’s valuation?
GSK has moved focus toward innovative biopharmaceuticals, reducing reliance on legacy drugs like PAXIL.

5. What valuation metrics are relevant?
Given its legacy status, PAXIL’s valuation hinges on residual revenues, licensing prospects, and market share in niche segments rather than growth metrics typical for new drugs.

---

References

1. GSK Annual Reports, 2014–2022
2. FDA and EMA Patent Listings, 2013–2022
3. IMS Health Data, 2004–2021
4. MarketWatch, "Antidepressant Market Overview," 2022
5. IQVIA Data, "Generic Drug Penetration," 2023